MSN 571 SEC2 WEEK 3 DQ1 (IN PROGRESS) Q1. Please briefly discuss the first-line treatment recommendations from JNC8 and the AHA/ACC for a patient with no other major comorbidities.

With the 2033 Joint National Committee's seventh report (JNC 7) turning obsolete and

the 2011 Institute of Medicine report requesting a better, evidence-based guiding principle. 7, 8,

(the Right Joint National Committee (JNC 8) was at first selected to develop an up-to-date

treatment guideline for high blood pressure (HTN) under the indications of the National

Institutes of Health (NIH). The NIH eventually withdrew from the regulation development

practice at the end of the JNC 8’s development; nevertheless, the panel determined to make

public their proposals autonomously.

Worldwide, hypertension (HTN) is the leading risk factor for cardiovascular disease

(CVD) mortality and morbidity. In this Nation, hypertension is placed first among modifiable

risk factors in the populace due to CVD risk, accountable for the most significant part of

coronary heart disease (CHD), heart failure (HF), and stroke incidents. In adults with HTN, the

control of HTP with antihypertensive treatment reduces the chances of CVD and mortality from

all causes (Carey et al., 2021).

The panel members selected for the Eight Joint National Committee (JNC-8) revealed a

report proposing a higher BP goal SBP/DBP<150/90 mm Hg for adults > 60 years in comparison

with the 2003 JNC-7 recommended target SBP/DBP <140/90 MM Hg. A small group report

from five out of 17 JNC-8 panel participants informed that relaxation of the blood pressure target

could decrease the amount of antihypertensive medication and the level of control of blood

pressure (Carey et al., 2021).

The panel members selected for the Eight Joint National Committee (JNC-8) revealed a

report proposing a higher BP goal SBP/DBP<150/90 mm Hg for adults > 60 years in comparison

with the 2003 JNC-7 recommended target SBP/DBP <140/90 MM Hg. A small group report

from five out of 17 JNC-8 panel participants informed that relaxation of the blood pressure target

could decrease the amount of antihypertensive medication and the level of control of blood

pressure (Carey et al., 2021